<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599235</url>
  </required_header>
  <id_info>
    <org_study_id>LREC/2004/4/13</org_study_id>
    <secondary_id>LREC/2004/4/13</secondary_id>
    <nct_id>NCT00599235</nct_id>
  </id_info>
  <brief_title>Sildenafil and Exercise Capacity in Hypertension</brief_title>
  <official_title>Effects of the Selective Phosphodiesterase Type 5 Inhibitor Sildenafil Citrate on Exercise Capacity and Vascular Function in Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <brief_summary>
    <textblock>
      Hypertension (persistently elevated blood pressure) is a major risk factor for heart disease
      and stroke. Hypertensive individuals show a reduced exercise capacity, which is present from
      a very early stage and contributes to their increased cardiovascular risk. Sildenafil belongs
      to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors, and it works by
      enhancing the effects of nitric oxide, a substance that dilates blood vessels and increases
      blood flow. We hypothesize that sildenafil, because of its effect on nitric oxide and blood
      flow, will improve exercise capacity in hypertensive patients. Therefore, the main aim of the
      study is to investigate the effects of PDE5 inhibition on exercise capacity and vascular
      function in hypertension, and to compare these effects in hypertensive patients and healthy
      controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen uptake (VO2) during exercise</measure>
    <time_frame>1 week of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise systolic blood pressure</measure>
    <time_frame>Maximal exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity and pulse wave analysis</measure>
    <time_frame>Before and after maximal exercise</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>50mg 3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydralazine</intervention_name>
    <description>25mg 3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male (age range: 18 - 70 years)

          -  Appropriate blood pressure range

          -  Hypertensive - Systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg

          -  Controls - Systolic BP &lt;140 mmHg and diastolic BP &lt;90mmHg

          -  Written informed consent

        Exclusion Criteria:

          -  Female

          -  History of coronary artery, cerebrovascular or peripheral vascular disease within the
             last 6 months

          -  Total cholesterol &gt;6.5 mmol/L

          -  Current alcohol abuse

          -  Diabetes mellitus

          -  Asthma

          -  Taking any anti-hypertensive, vasoactive or endothelial function modifying drugs which
             cannot be withdrawn for the purpose of the study

          -  ECG evidence of clinically significant arrhythmia or cardiac ischaemia

          -  Clinically significant abnormality on screening blood test

          -  Contraindication to strenuous exercise

          -  Current involvement in other research projects

          -  Other clinically relevant conditions

          -  Lack of written informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa M Attinà, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Webb, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh - Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <last_update_submitted>April 7, 2010</last_update_submitted>
  <last_update_submitted_qc>April 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marise Bucukoglu</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>PDE5 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

